Upgrade to SI Premium - Free Trial

Piper Sandler Reiterates Overweight Rating on Biogen (BIIB)

July 14, 2026 7:56 AM
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $225.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "Expert ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments